# Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

> **NCT05995119** · EARLY_PHASE1 · COMPLETED · sponsor: **TAHO Pharmaceuticals Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers
- Fasting
- Fed

## Interventions

- **DRUG:** Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)

## Key facts

- **NCT ID:** NCT05995119
- **Lead sponsor:** TAHO Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-05
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-01-13
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995119, "Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05995119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*